Host: |
Rabbit |
Applications: |
WB/ELISA |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.01% Thimerosal, 50% Glycerol, pH 7.3. |
Purification: |
Affinity purification |
Concentration: |
Lot specific |
Dilution Range: |
WB:1:500-1:2000ELISA:Recommended starting concentration is 1 Mu g/mL. Please optimize the concentration based on your specific assay requirements. |
Gene Symbol: |
LPAR3 |
Gene ID: |
23566 |
Uniprot ID: |
LPAR3_HUMAN |
Immunogen Region: |
150-250 aa |
Specificity: |
A synthetic peptide corresponding to a sequence within amino acids 150-250 of human LPAR3 (NP_036284.1). |
Immunogen Sequence: |
LLVWAIAIFMGAVPTLGWNC LCNISACSSLAPIYSRSYLV FWTVSNLMAFLIMVVVYLRI YVYVKRKTNVLSPHTSGSIS RRRTPMKLMKTVMTVLGAFV V |
Tissue Specificity | Most abundantly expressed in prostate, testes, pancreas, and heart, with moderate levels in lung and ovary. No detectable expression in brain, placenta, liver, skeletal muscle, kidney, spleen, thymus, small intestine, colon, or peripheral blood leukocytes. |
Function | Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. May play a role in the development of ovarian cancer. Seems to be coupled to the G(i)/G(o) and G(q) families of heteromeric G proteins. |
Protein Name | Lysophosphatidic Acid Receptor 3Lpa Receptor 3Lpa-3Lysophosphatidic Acid Receptor Edg-7 |
Database Links | Reactome: R-HSA-416476Reactome: R-HSA-418594Reactome: R-HSA-419408 |
Cellular Localisation | Cell MembraneMulti-Pass Membrane Protein |
Alternative Antibody Names | Anti-Lysophosphatidic Acid Receptor 3 antibodyAnti-Lpa Receptor 3 antibodyAnti-Lpa-3 antibodyAnti-Lysophosphatidic Acid Receptor Edg-7 antibodyAnti-LPAR3 antibodyAnti-EDG7 antibodyAnti-LPA3 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance